Published in J Virol on September 01, 2001
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
Quasispecies theory and the behavior of RNA viruses. PLoS Pathog (2010) 3.19
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The restriction factors of human immunodeficiency virus. J Biol Chem (2012) 2.36
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol (2005) 1.63
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett (2007) 1.62
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol (2008) 1.50
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol (2004) 1.50
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog (2010) 1.43
Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One (2009) 1.39
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol (2008) 1.33
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
APOBECs and virus restriction. Virology (2015) 1.27
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol (2010) 1.22
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol (2009) 1.17
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol (2012) 1.14
APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol (2012) 1.14
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS (2008) 1.09
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog (2014) 1.07
Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol (2010) 1.04
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
HIV restriction by APOBEC3 in humanized mice. PLoS Pathog (2013) 1.00
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet (2014) 1.00
Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs. MedGenMed (2005) 0.97
APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol (2013) 0.97
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem (2010) 0.97
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog (2014) 0.95
In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT. Virology (2007) 0.93
Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol (2011) 0.93
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One (2011) 0.91
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
HIV-1 quasispecies delineation by tag linkage deep sequencing. PLoS One (2014) 0.86
APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology (2012) 0.86
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1. Retrovirology (2014) 0.84
APOBEC3F determinants of HIV-1 Vif sensitivity. J Virol (2014) 0.82
In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins. Virology (2011) 0.81
Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation. PLoS Pathog (2016) 0.80
Effects of Korean Red Ginseng and HAART on vif Gene in 10 Long-Term Slow Progressors over 20 Years: High Frequency of Deletions and G-to-A Hypermutation. Evid Based Complement Alternat Med (2013) 0.78
No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques. J Virol (2012) 0.78
Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Retrovirology (2015) 0.78
Mechanism of enhanced HIV restriction by virion coencapsidated cytidine deaminases APOBEC3F and APOBEC3G. J Virol (2016) 0.76
APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res (2016) 0.76
Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses (2014) 0.76
HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity. Retrovirology (2014) 0.76
A classification approach for genotyping viral sequences based on multidimensional scaling and linear discriminant analysis. BMC Bioinformatics (2010) 0.76
Codon pairs of the HIV-1 vif gene correlate with CD4+ T cell count. BMC Infect Dis (2013) 0.76
APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms. Front Microbiol (2016) 0.75
Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy. Virol J (2016) 0.75
In vivo HIV-1 hypermutation and viral loads among antiretroviral-naive Brazilian patients. AIDS Res Hum Retroviruses (2014) 0.75
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs. J Int AIDS Soc (2005) 0.75
The mutable vaccine for mutable viruses. Immunotherapy (2017) 0.75
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. J Mol Biol (2017) 0.75
'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res (1991) 19.71
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA (1987) 7.24
The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle. Naturwissenschaften (1977) 7.19
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A (1993) 5.42
RNA virus populations as quasispecies. Curr Top Microbiol Immunol (1992) 5.42
Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol (1991) 5.03
Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell (1988) 4.90
Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci U S A (1990) 4.72
Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature (1992) 4.11
Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem (1989) 3.80
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A (1993) 3.45
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene (1985) 3.42
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11
Detecting hypermutations in viral sequences with an emphasis on G --> A hypermutation. Bioinformatics (2000) 3.07
Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro. J Virol (1991) 2.91
High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. Biotechniques (1996) 2.63
G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A (1994) 2.52
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38
Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry (1992) 2.27
Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A (1994) 2.21
A new type of G-->A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses (1993) 2.19
The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology (1991) 2.15
Vesicular stomatitis virus defective interfering particles can contain extensive genomic sequence rearrangements and base substitutions. Cell (1984) 2.13
International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res (1994) 1.86
DNA sequence preferences of several AT-selective minor groove binding ligands. Nucleic Acids Res (1995) 1.82
The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res (1989) 1.76
Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J Biol Chem (1983) 1.74
Biological asymmetries and the fidelity of eukaryotic DNA replication. Bioessays (1992) 1.73
Extension of mismatched 3' termini of DNA is a major determinant of the infidelity of human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A (1989) 1.71
Modulation of mutagenesis by deoxyribonucleotide levels. Annu Rev Genet (1991) 1.69
Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. Nucleic Acids Res (1996) 1.67
Biased (A-->I) hypermutation of animal RNA virus genomes. Curr Opin Genet Dev (1994) 1.65
Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol (2000) 1.58
HIV genetic variation is directed and restricted by DNA precursor availability. J Mol Biol (1997) 1.48
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med (1999) 1.48
The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology (1996) 1.42
The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. J Virol (1992) 1.41
Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol (1998) 1.40
A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. Virology (1995) 1.38
DNA precursor asymmetries, replication fidelity, and variable genome evolution. Bioessays (1992) 1.35
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes (1996) 1.33
Modification of retroviral RNA by double-stranded RNA adenosine deaminase. J Virol (1995) 1.31
Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS (1991) 1.27
Polyethylene glycol derivatives of base and sequence specific DNA ligands: DNA interaction and application for base specific separation of DNA fragments by gel electrophoresis. Nucleic Acids Res (1981) 1.26
Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol (2000) 1.25
Erratic G-->A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus. Virology (1995) 1.18
The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate. J Virol (1997) 1.16
Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J Virol (1996) 1.14
Functional and biological properties of an avian variant long terminal repeat containing multiple A to G conversions in the U3 sequence. J Virol (1994) 1.14
The role of the cell cycle in HIV-1 infection. Adv Exp Med Biol (1995) 1.13
Using mismatched primer-template pairs in touchdown PCR. Biotechniques (1994) 1.12
Deoxyribonucleoside 5'-triphosphate pool fluctuations during the mammalian cell cycle. Biochim Biophys Acta (1972) 1.11
Nucleotide composition as a driving force in the evolution of retroviruses. J Mol Evol (1994) 1.11
Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation. Virology (1997) 1.11
A simple and rapid electrophoresis method to detect sequence variation in PCR-amplified DNA fragments. Nucleic Acids Res (1995) 1.09
Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction. Nucleic Acids Res (1995) 1.07
Analysis of genetic heterogeneity within the type strain of satellite tobacco mosaic virus reveals variants and a strong bias for G to A substitution mutations. Virology (1992) 0.98
High resolution analysis of HIV-1 quasispecies in the brain. AIDS (1995) 0.94
Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction. Virology (2000) 0.93
Antibiotic induced electrophoretic mobility shifts of DNA restriction fragments. Nucleic Acids Res (1979) 0.92
Effect of hydroxyurea and 5-fluorodeoxyuridine on deoxyribonucleoside triphosphate pools early in phytohemagglutinin-stimulated human lymphocytes. Biochem Pharmacol (1982) 0.90
Cell cycle-dependent metabolism of pyrimidine deoxynucleoside triphosphates in CEM cells. J Biol Chem (1997) 0.85
HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping. AIDS Res Hum Retroviruses (1998) 0.84
Compositional bimodality and evolution of retroviral genomes. Gene (1992) 0.82
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science (1993) 8.49
Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses (1995) 7.12
Recombination in HIV-1. Nature (1995) 5.72
Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med (1989) 4.72
The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative Expenses. Anesthesiology (1997) 3.92
Trends in perinatal transmission of HIV/AIDS in the United States. JAMA (1999) 3.86
Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito. Nature (1998) 3.56
Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS (1993) 3.52
Detection of diverse HIV-1 genetic subtypes in the USA. Lancet (1995) 3.41
HeartCare: an Internet-based information and support system for patient home recovery after coronary artery bypass graft (CABG) surgery. J Adv Nurs (2001) 3.36
Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med (1993) 3.34
Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol (1996) 2.83
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68
Marriage, monogamy and HIV: a profile of HIV-infected women in south India. Int J STD AIDS (2000) 2.59
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis (1994) 2.42
Communication between GPs and cooperatives is poor for terminally ill patients. BMJ (1997) 2.41
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol (1995) 2.35
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet (2001) 2.19
Interferon therapy for condylomata acuminata. N Engl J Med (1986) 2.16
Analysis of Tn7 transposition. Mol Gen Genet (1986) 2.08
Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.97
Next-generation sequencing: the solution for high-resolution, unambiguous human leukocyte antigen typing. Hum Immunol (2010) 1.95
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses (1996) 1.92
Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res Hum Retroviruses (1994) 1.90
Selective neuronal targeting in prion disease. Neuron (1997) 1.82
Screening for Duchenne muscular dystrophy. Arch Dis Child (1989) 1.78
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med (2000) 1.76
Anogenital warts in childhood. Child Abuse Negl (1989) 1.75
Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr (1992) 1.72
Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A (1993) 1.67
Study of restriction fragment length polymorphism analysis and spoligotyping for epidemiological investigation of Mycobacterium bovis infection. J Clin Microbiol (1999) 1.64
Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. JAMA (1996) 1.64
Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J Virol (1997) 1.62
Acquisition of protease resistance by prion proteins in scrapie-infected cells does not require asparagine-linked glycosylation. Proc Natl Acad Sci U S A (1990) 1.59
Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet (2002) 1.50
Primary immunisations in Liverpool. II: Is there a gap between consent and completion? Arch Dis Child (1993) 1.49
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis (2000) 1.48
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med (1999) 1.48
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 1.46
Quantitative measurement of calcium flux through muscle and neuronal nicotinic acetylcholine receptors. J Neurosci (1994) 1.45
Uncertainty and opposition of medical students toward assisted death practices. J Pain Symptom Manage (2001) 1.43
Double stapled transabdominal anastomosis for one-stage resection of acute sigmoid volvulus. Br J Surg (1997) 1.40
Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS (2001) 1.40
Fixed drug eruptions in children. J Pediatr (1999) 1.40
Primary immunisations in Liverpool. I: Who withholds consent? Arch Dis Child (1993) 1.40
A coordinated programme will identify needs. Practice nurses' role in screening elderly people. Prof Nurse (1991) 1.39
Preventing perinatal HIV infection. How far have we come? JAMA (1996) 1.39
Effects of methyl beta-cyclodextrin on EDHF responses in pig and rat arteries; association between SK(Ca) channels and caveolin-rich domains. Br J Pharmacol (2007) 1.39
Euphemisms in nursing's future. 1975. Image J Nurs Sch (1997) 1.37
Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol (2003) 1.34
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine (1993) 1.32
Characterization of subtype A HIV-1 from Africa by full genome sequencing. AIDS (1999) 1.31
ESGE-ESGENA Guideline: cleaning and disinfection in gastrointestinal endoscopy. Endoscopy (2008) 1.30
Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology (1993) 1.26
A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD. AIDS Res Hum Retroviruses (2007) 1.25
Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. J Biol Chem (1996) 1.25
Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med (2003) 1.21
Unusual electrocardiographic presentation of right ventricular myocardial infarction. Tex Heart Inst J (1996) 1.21
A three-year study of impetigo in Sydney. Med J Aust (1987) 1.20
D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology (2003) 1.20
The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. Virology (2001) 1.20
First CRF01_AE/B recombinant of HIV-1 is found in Thailand. AIDS (2001) 1.19
Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med (1995) 1.17
Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol (2001) 1.17
A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med (1991) 1.13
Vulvar disease in children: a clinical audit of 130 cases. Pediatr Dermatol (2000) 1.12
99th ENMC international workshop: myotonic dystrophy: present management, future therapy. 9-11 November 2001, Naarden, The Netherlands. Neuromuscul Disord (2002) 1.12
Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate (1999) 1.11
Patient tolerance of craniotomy performed with the patient under local anesthesia and monitored conscious sedation. Neurosurgery (1998) 1.10
Use of ultrasonography in the diagnosis of childhood pilomatrixoma. Pediatr Dermatol (2000) 1.10
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 1.09
Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol (2000) 1.08
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother (2000) 1.07
Correlates of HIV-1 seropositivity among young men in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.07
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate (1999) 1.05
Provider-initiated HIV testing and counseling in TB clinical settings: tools for program implementation. Int J Tuberc Lung Dis (2008) 1.05
Clostridium perfringens beta-toxin forms potential-dependent, cation-selective channels in lipid bilayers. Infect Immun (2000) 1.05
Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol (2001) 1.05
The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (1984) 1.04
Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. Perinatal AIDS Collaborative Transmission Studies. AIDS (1998) 1.04
Treatment of macrophages with oxidized low-density lipoprotein increases their intracellular glutathione content. Biochem J (1991) 1.04
In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach. J Virol (2005) 1.03
Pregnancy Risk Assessment Monitoring System (PRAMS): unintended pregnancy among women having a live birth. PRAMS Working Group. J Womens Health Gend Based Med (1999) 1.02
The effect of asymptomatic infection with HTLV-III on the response of anogenital warts to intralesional treatment with recombinant alpha 2 interferon. J Infect Dis (1986) 1.02
Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis (1997) 1.01
Comparison of tetracycline and minocyclie transport in Escherichia Coli. Antimicrob Agents Chemother (1975) 1.01
Multiple introductions of HIV-1 subtype E into the western hemisphere. Lancet (1995) 1.01
Disseminated invasive infection due to Metarrhizium anisopliae in an immunocompromised child. J Clin Microbiol (1998) 0.99
Apolipoprotein B synthesis by human liver and intestine in vitro. Proc Natl Acad Sci U S A (1986) 0.98